NEW YORK, NY / ACCESSWIRE / October 5, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have been filed on behalf of the shareholders of the following public companies. Shareholders interested in serving as lead plaintiffs have until the listed time limits to file a motion with the court. See the links provided for more details on the cases. There are no costs or obligations for you.

AMPE shareholders click here: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32424&wire=1
DDL shareholders click here: https://www.zlk.com/pslra-1/dingdong-lawsuit-submission-form?prid=32424&wire=1
PLTR shareholders click here: https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=32424&wire=1

* ADDITIONAL INFORMATION BELOW *

Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

This lawsuit is being brought on behalf of any person or entity that purchased or otherwise acquired between December 29, 2020 and August 3, 2022, inclusive, Ampio common stock.
Deadline for Lead Plaintiff : October 17, 2022
TO LEARN MORE VISIT: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32424&wire=1

According to the lawsuit filed, (i) the defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) the defendants inflated the results of the AP-013 study and the timing of the unblinding of the data from the AP-013 study; and (iii) as a result of the foregoing, Defendants’ statements about the Company’s business, operations and prospects were materially misleading and/or lacked any reasonable basis.

Dingdong (Caiman) Ltd. (NYSE:DDL)

This lawsuit is being brought on behalf of persons who purchased or otherwise acquired Dingdong American Depository Shares pursuant to the F-1 registration statements and related prospectus on Form 424B4 issued in connection with Dingdong’s June 2021 IPO.
Deadline for Lead Plaintiff : October 24, 2022
TO LEARN MORE VISIT: